Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies u…

GVHD - Graft-Versus-Host Disease

Estimated

~$10 – $7,500

Northwell HealthNCT07675174